GlassScriptPhysician profile
Anjana Ranganathan
NPI 1437324845
$6,649.69
in general payments reported to CMS, 2019-2025
58 companies · $1,110 in 2025
The $1,110 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,452 · 2020: $368 · 2021: $696 · 2022: $899 · 2023: $1,128 · 2024: $996 · 2025: $1,110.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,135 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,135.30 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $535.75 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $492.34 | 2019-2025 | Datroway, Imfinzi, Tagrisso |
| Daiichi Sankyo INC. | $305.20 | 2022-2025 | Enhertu, Injectafer, Vanflyta |
| Tesaro, INC. | $259.68 | 2019 | |
| Abbvie INC. | $242.06 | 2021-2025 | |
| Janssen Biotech, INC. | $232.40 | 2022-2025 | Darzalex, Talvey, Erleada |
| Seagen INC. | $221.63 | 2020-2023 | Adcetris, Tukysa |
| Amgen INC. | $219.16 | 2020-2023 | Kyprolis, Vectibix, Nplate |
| Pharmacyclics LLC, An Abbvie Company | $215.96 | 2019-2023 | Imbruvica, Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $214.45 | 2021-2024 | Ninlaro, Fruzaqla, Alunbrig |
| Celgene Corporation | $212.95 | 2019-2025 | Reblozyl, Opdualag |
| E.R. Squibb & Sons, L.L.C. | $212.58 | 2019-2025 | Opdualag, Opdivo |
| Genzyme Corporation | $205.84 | 2019-2025 | |
| Eagle Pharmaceuticals, INC. | $204.41 | 2023-2024 | |
| Lilly USA, LLC | $186.60 | 2019-2023 | Retevmo, Jaypirca, Verzenio |
Show all 58 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $185.73 | 2019-2025 | Keytruda, Welireg |
| Bayer Healthcare Pharmaceuticals INC. | $179.75 | 2019-2025 | |
| Eisai INC. | $168.17 | 2019-2024 | |
| Genentech USA, INC. | $153.43 | 2019-2025 | Polivy |
| Pfizer INC. | $148.58 | 2021-2025 | |
| Puma Biotechnology, INC. | $138.39 | 2019-2024 | |
| Acrotech Biopharma INC. | $115.73 | 2021-2025 | Beleodaq |
| Astellas Pharma US INC | $115.04 | 2020-2025 | Vyloy, Xospata |
| Glaxosmithkline, LLC. | $112.21 | 2021-2025 | Zejula, Jemperli, Ojjaara |
| Foundation Medicine, INC. | $107.50 | 2019-2023 | |
| Karyopharm Therapeutics INC. | $99.32 | 2023-2025 | Xpovio |
| Gilead Sciences, INC. | $94.59 | 2021-2025 | Trodelvy |
| Incyte Corporation | $88.33 | 2022-2024 | Monjuvi, Pemazyre, Jakafi |
| Stemline Therapeutics INC. | $86.04 | 2022-2025 | Orserdu |
| Kite Pharma, INC. | $82.36 | 2021-2024 | Yescarta |
| Ipsen Biopharmaceuticals, INC | $80.46 | 2023-2025 | Somatuline Depot, Onivyde |
| Exelixis INC. | $69.43 | 2019-2024 | Cabometyx |
| Kyowa Kirin, INC. | $54.05 | 2021-2024 | Poteligeo |
| Adc Therapeutics America, INC. | $53.57 | 2022-2024 | |
| Emd Serono, INC. | $46.26 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $42.80 | 2021-2025 | Ultomiris |
| Array Biopharma INC | $41.71 | 2021-2025 | Xalkori, Lorbrena, Braftovi |
| Pharmaessentia USA Corporation | $41.65 | 2024-2025 | Besremi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $29.09 | 2019 | |
| Deciphera Pharmaceuticals INC. | $25.59 | 2021-2025 | Tgct, Qinlock |
| Beigene USA, INC. | $24.99 | 2022 | |
| Morphosys, US INC. | $24.97 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.48 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.80 | 2024 | Amvuttra |
| Genmab U.S., INC. | $23.46 | 2025 | Tivdak |
| Mirati Therapeutics, INC. | $22.82 | 2024 | Krazati |
| Dova Pharmaceuticals | $19.16 | 2020 | |
| Organon LLC | $18.22 | 2023 | Ontruzant |
| Heron Therapeutics, INC. | $17.83 | 2022 | |
| Blueprint Medicines Corporation | $17.00 | 2022 | |
| Rigel Pharmaceuticals, INC. | $15.87 | 2024 | Rezlidhia, Tavalisse |
| Clinigen, INC. | $15.36 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $14.99 | 2025 | Sancuso |
| Azurity Pharmaceuticals, INC. | $14.14 | 2025 | Vivimusta |
| Acceleron Pharma, INC. | $13.82 | 2021 | |
| Emmaus Medical, INC. | $13.17 | 2022 | |
| Clovis Oncology, INC. | $13.15 | 2019 | |
| G1 Therapeutics, INC. | $11.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anjana Ranganathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.